Cancer of unknown primary with EGFR mutation successfully treated with targeted therapy directed by clinical next-generation sequencing: a case report

BACKGROUND: Cancer of unknown primary (CUP) is usually treated with nonselective and empirical chemotherapy; however, its prognosis is generally poor, with a median survival of less than a year. Thus, clinicians eagerly await the development of more effective treatment strategies. In recent years, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitani, Yosuke, Kanai, Masashi, Kou, Tadayuki, Kataoka, Shigeki, Doi, Keitaro, Matsubara, Junichi, Ohashi, Shinya, Matsumoto, Shigemi, Muto, Manabu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709432/
https://www.ncbi.nlm.nih.gov/pubmed/33267781
http://dx.doi.org/10.1186/s12885-020-07640-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709432/
https://www.ncbi.nlm.nih.gov/pubmed/33267781
http://dx.doi.org/10.1186/s12885-020-07640-4

Ejemplares similares